Dose Suggestions for Intravenous Colistin in Pediatric Patients

Caution Required

Research output: Contribution to journalLetterOther

3 Citations (Scopus)

Abstract

To the Editor—Mesini et al reported plasma concentrations of colistin in 7 pediatric patients (aged 46 days to 13 years) who were receiving intravenously the inactive prodrug colistimethate; across all patients, plasma colistin concentrations were measured on 13 occasions [1]. That report has been the subject of critical appraisal by Magréault et al [2], who expressed substantial concerns about the magnitude of the plasma colistin concentrations reported and the pharmacokinetic analysis conducted by Mesini and coworkers. I agree with Magréault et al and amplify their comments. I have very substantial concerns about the dosing recommendations implicitly presented in the report of Mesini and coworkers.
Original languageEnglish
Pages (from-to)810-811
Number of pages2
JournalClinical Infectious Diseases
Volume66
Issue number5
DOIs
Publication statusPublished - 10 Feb 2018

Cite this

@article{ca1581d2728942969b0155cb3ff27cf7,
title = "Dose Suggestions for Intravenous Colistin in Pediatric Patients: Caution Required",
abstract = "To the Editor—Mesini et al reported plasma concentrations of colistin in 7 pediatric patients (aged 46 days to 13 years) who were receiving intravenously the inactive prodrug colistimethate; across all patients, plasma colistin concentrations were measured on 13 occasions [1]. That report has been the subject of critical appraisal by Magr{\'e}ault et al [2], who expressed substantial concerns about the magnitude of the plasma colistin concentrations reported and the pharmacokinetic analysis conducted by Mesini and coworkers. I agree with Magr{\'e}ault et al and amplify their comments. I have very substantial concerns about the dosing recommendations implicitly presented in the report of Mesini and coworkers.",
author = "Nation, {Roger L.}",
year = "2018",
month = "2",
day = "10",
doi = "10.1093/cid/cix1048",
language = "English",
volume = "66",
pages = "810--811",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

Dose Suggestions for Intravenous Colistin in Pediatric Patients : Caution Required. / Nation, Roger L.

In: Clinical Infectious Diseases, Vol. 66, No. 5, 10.02.2018, p. 810-811.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Dose Suggestions for Intravenous Colistin in Pediatric Patients

T2 - Caution Required

AU - Nation, Roger L.

PY - 2018/2/10

Y1 - 2018/2/10

N2 - To the Editor—Mesini et al reported plasma concentrations of colistin in 7 pediatric patients (aged 46 days to 13 years) who were receiving intravenously the inactive prodrug colistimethate; across all patients, plasma colistin concentrations were measured on 13 occasions [1]. That report has been the subject of critical appraisal by Magréault et al [2], who expressed substantial concerns about the magnitude of the plasma colistin concentrations reported and the pharmacokinetic analysis conducted by Mesini and coworkers. I agree with Magréault et al and amplify their comments. I have very substantial concerns about the dosing recommendations implicitly presented in the report of Mesini and coworkers.

AB - To the Editor—Mesini et al reported plasma concentrations of colistin in 7 pediatric patients (aged 46 days to 13 years) who were receiving intravenously the inactive prodrug colistimethate; across all patients, plasma colistin concentrations were measured on 13 occasions [1]. That report has been the subject of critical appraisal by Magréault et al [2], who expressed substantial concerns about the magnitude of the plasma colistin concentrations reported and the pharmacokinetic analysis conducted by Mesini and coworkers. I agree with Magréault et al and amplify their comments. I have very substantial concerns about the dosing recommendations implicitly presented in the report of Mesini and coworkers.

UR - http://www.scopus.com/inward/record.url?scp=85051675011&partnerID=8YFLogxK

U2 - 10.1093/cid/cix1048

DO - 10.1093/cid/cix1048

M3 - Letter

VL - 66

SP - 810

EP - 811

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -